Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) Income towards Parent Company (2021 - 2025)

Historic Income towards Parent Company for HeartSciences (HSCS) over the last 5 years, with Q4 2025 value amounting to -$2.4 million.

  • HeartSciences' Income towards Parent Company fell 1190.44% to -$2.4 million in Q4 2025 from the same period last year, while for Oct 2025 it was -$9.1 million, marking a year-over-year decrease of 1701.1%. This contributed to the annual value of -$8.9 million for FY2025, which is 3293.13% down from last year.
  • As of Q4 2025, HeartSciences' Income towards Parent Company stood at -$2.4 million, which was down 1190.44% from -$2.1 million recorded in Q3 2025.
  • HeartSciences' Income towards Parent Company's 5-year high stood at -$752051.0 during Q3 2021, with a 5-year trough of -$2.6 million in Q1 2025.
  • Moreover, its 5-year median value for Income towards Parent Company was -$1.8 million (2022), whereas its average is -$1.7 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first plummeted by 10925.5% in 2022, then surged by 2054.79% in 2023.
  • HeartSciences' Income towards Parent Company (Quarter) stood at -$1.0 million in 2021, then tumbled by 74.7% to -$1.8 million in 2022, then grew by 3.28% to -$1.7 million in 2023, then fell by 20.26% to -$2.1 million in 2024, then decreased by 11.9% to -$2.4 million in 2025.
  • Its last three reported values are -$2.4 million in Q4 2025, -$2.1 million for Q3 2025, and -$2.1 million during Q2 2025.